Table 4.

Relationship between expression of microtubule components, response, progression on therapy, and survival in 93 NSCLC patients treated with a vinorelbine-based regimen

nResponse rate (%)PProgression rate (%)PPFS (d)POS (d)P
Class II β-tubulin
    ≤50%59280.930.00.1631500.152260.12
    >50%3426.946.285184
Class III β-tubulin
    ≤50%4934.40.218.70.0092083060.001
    >50%4422.747.7890.002162
Δ2 α-tubulin*
    ≤50%4024.20.721.20.0181730.32430.045
    >50%5228.647.6105168
  • Abbreviations: PFS, progression-free survival; Progression, progression on therapy; OS, overall survival.

  • * Data missing for one patient.